Macrophage Migration Inhibitory Factor for Diagnosing Endometriosis and Its Severity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04091997

Enrollment

300

Registered

2019-09-17

Start date

2016-03-31

Completion date

2018-09-30

Last updated

2019-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Keywords

Macrophage migration inhibitory factor, Endometriosis, Laparoscopy

Brief summary

Endometriosis is a chronic disease affecting women of reproductive age. Macrophage migration inhibitory factor (MIF) is one of non-invasive blood biomarker that was detected in sera of endometriotic patients.The aim of this study was to evaluate the value of serum macrophage migration inhibitory factor in diagnosing endometriosis in women with infertility and chronic pelvic pain and correlate its level with the stage of the disease. Three hundred patient candidate for diagnostic laparoscopy were included in a case-control observational study

Detailed description

observational case-control study conducted in Fayoum University hospital from March 2016 till September 2018. Three hundred women candidate for diagnostic laparoscopy for either infertility or gynecologic chronic pelvic pain were included. The study group included patients with diagnostic criteria of endometriosis. The control group included other causes of infertility or pelvic pain.

Interventions

DIAGNOSTIC_TESTserum Eliza assay

laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

19 Years to 40 Years

Healthy volunteers

Inclusion criteria

* postmenstrual women * in childbearing period, * presenting with either gynecologic chronic pelvic pain (CPP) or infertility * indicated and fit for diagnostic laparoscopy. * All women must have no hormonal treatment for the last 3 months and.

Exclusion criteria

* Women with bleeding tendency, * suspicious of gynecologic malignancy or * active infection

Design outcomes

Primary

Measure	Time frame	Description
level of serum macrophage migration inhibitory factor and stage of the disease	one year	serum MIF is a promising marker for noninvasive diagnosis of severity of endometriosis

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026